Analysis of a Systemic Inflammatory Biomarker in Advanced Bile Tract Carcinoma Treated with Anti-PD-1 Therapy: Prognostic and Predictive Significance of Lung Immune Prognostic Index Score
Table 5
Univariate and multivariate analyses of factors associated with OS and PFS.
(a)
Patient characteristics
Univariate analysis
Multivariate analysis
OS
HR (95% CI)
HR (95% CI)
ECOG performance status
0-1
1 [ref.]
1 [ref.]
≥2
5.473 (2.099-14.266)
0.001
5.383 (2.058-14.081)
0.001
Lines of immunotherapy
<2
1 [ref.]
1 [ref.]
≥2
1.678 (1.021-2.758)
0.041
1.523 (0.919-2.526)
0.103
LIPI
The good
1 [ref.]
1 [ref.]
The intermediate/poor
1.892 (1.085-3.299)
0.024
1.877 (1.076-3.275)
0.027
(b)
Patient characteristics
Univariate analysis
Multivariate analysis
PFS
HR
HR
Lines of immunotherapy
≥2
1 [ref.]
1 [ref.]
<2
1.963 (1.247-3.091)
0.004
1.677 (1.055-2.665)
0.029
ECOG performance status
≥2
1 [ref.]
1 [ref.]
0-1
2.558 (1.022-6.404)
0.045
2.348 (0.927-5.946)
0.072
LIPI
The good
1 [ref.]
1 [ref.]
The intermediate/poor
2.524 (1.540-4.137)
<0.001
2.301 (1.395-3.796)
0.001
PFS: progression-free survival; OS: overall survival; LIPI: lung immune prognostic index; ECOG PS: Eastern Cooperative Oncology Group performance status scores.
